Published in Cancer Res on August 16, 2010
Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood (2013) 1.80
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet (2012) 1.07
Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees. EMBO Rep (2011) 1.02
Cytosine methylation and hydroxymethylation mark DNA for elimination in Oxytricha trifallax. Genome Biol (2012) 1.00
Improvement of cardiac function in mouse myocardial infarction after transplantation of epigenetically-modified bone marrow progenitor cells. PLoS One (2011) 0.93
Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. Clin Epigenetics (2015) 0.88
Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res (2011) 0.87
Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenetics (2014) 0.86
Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure. PLoS Genet (2013) 0.86
Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis (2012) 0.85
Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics (2014) 0.83
Epigenetic synergy between decitabine and platinum derivatives. Clin Epigenetics (2015) 0.82
Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery. PLoS One (2011) 0.81
Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies. PLoS One (2013) 0.80
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. Cancer Res (2015) 0.80
Promoter methylation-independent reactivation of PAX1 by curcumin and resveratrol is mediated by UHRF1. Clin Exp Med (2015) 0.79
3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models. BMC Pharmacol Toxicol (2013) 0.79
Human factors and pathways essential for mediating epigenetic gene silencing. Epigenetics (2014) 0.79
Persistence of furan-induced epigenetic aberrations in the livers of F344 rats. Toxicol Sci (2014) 0.77
A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Res (2014) 0.77
REPOSITIONING FDA-APPROVED DRUGS IN COMBINATION WITH EPIGENETIC DRUGS TO REPROGRAM COLON CANCER EPIGENOME. Mol Cancer Ther (2016) 0.75
Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine. BMC Cancer (2013) 0.75
Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells. Front Oncol (2017) 0.75
Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Res (2016) 0.75
Casticin inhibits the activity of transcription factor Sp1 and the methylation of RECK in MGC803 gastric cancer cells. Exp Ther Med (2016) 0.75
Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget (2017) 0.75
The epigenomics of cancer. Cell (2007) 30.91
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res (2004) 7.92
Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques (2003) 5.49
DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet (2000) 5.29
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol (2005) 5.02
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res (1998) 2.83
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res (2006) 2.69
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med (2004) 2.35
Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res (2001) 2.27
Mechanisms of epigenetic inheritance. Curr Opin Cell Biol (2007) 2.20
Making copies of chromatin: the challenge of nucleosomal organization and epigenetic information. Trends Cell Biol (2008) 1.95
Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in embryonic stem cells. EMBO Rep (2009) 1.89
CIMP, at last. Gastroenterology (2005) 1.74
Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res (2008) 1.69
Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mutat Res (2008) 1.61
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res (2006) 1.60
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood (2008) 1.52
Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol (1999) 1.49
Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res (2006) 1.46
Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci U S A (2004) 1.45
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res (2007) 1.40
Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene (2006) 1.36
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res (2009) 1.24
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics (2009) 1.17
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood (2007) 1.13
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene (2005) 1.06
5-Azadeoxycytidine-induced chromatin remodeling of the inactive X-linked HPRT gene promoter occurs prior to transcription factor binding and gene reactivation. J Biol Chem (1997) 0.91
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res (2004) 7.92
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet (2002) 4.06
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol (2007) 2.75
Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol (2003) 2.73
Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol (2003) 2.72
Epigenetics in cancer: what's the future? Oncology (Williston Park) (2011) 2.70
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res (2006) 2.69
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One (2008) 2.52
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Epigenetic changes in colorectal cancer. Cancer Metastasis Rev (2004) 2.35
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med (2006) 2.23
Cancer epigenetics. CA Cancer J Clin (2010) 2.16
High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res (2007) 2.09
DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst (2002) 2.04
Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res (2007) 2.02
Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res (2007) 2.02
Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2004) 2.01
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol (2005) 1.93
Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol (2008) 1.89
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev (2009) 1.88
CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol (2002) 1.83
Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques (2007) 1.78
CIMP, at last. Gastroenterology (2005) 1.74
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood (2008) 1.71
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood (2002) 1.65
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) 1.65
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Decitabine--bedside to bench. Crit Rev Oncol Hematol (2006) 1.59
Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A (2003) 1.57
Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis (2008) 1.57
Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol (2002) 1.56
Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol (2007) 1.56
DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer (2010) 1.55
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res (2010) 1.53
Epigenetic changes in solid and hematopoietic tumors. Semin Oncol (2005) 1.52
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood (2008) 1.52
Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. Cancer Biol Ther (2004) 1.50
An Sp1/Sp3 binding polymorphism confers methylation protection. PLoS Genet (2008) 1.49
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res (2007) 1.48
Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res (2006) 1.46
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One (2008) 1.46
Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci U S A (2004) 1.45
Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells. J Biol Chem (2003) 1.43
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res (2002) 1.42
Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res (2007) 1.40
Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res (2010) 1.38
Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Res (2003) 1.36
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
CpG island methylation profiling in human melanoma cell lines. Melanoma Res (2009) 1.35
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis (2009) 1.34
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica (2008) 1.33
Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res (2004) 1.33
Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res (2007) 1.33
DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res (2002) 1.31
Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res (2014) 1.30
The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology (2005) 1.30
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics (2012) 1.29